Advertisement
Canada markets closed

  • S&P/TSX

    24,471.17
    +168.91 (+0.70%)
     

  • S&P 500

    5,815.03
    +34.98 (+0.61%)
     

  • DOW

    42,863.86
    +409.74 (+0.97%)
     

  • CAD/USD

    0.7266
    -0.0011 (-0.16%)
     

  • CRUDE OIL

    75.49
    -0.36 (-0.47%)
     

  • Bitcoin CAD

    86,177.34
    -788.65 (-0.91%)
     

  • XRP CAD

    0.73
    -0.02 (-2.04%)
     

  • GOLD FUTURES

    2,674.20
    +34.90 (+1.32%)
     

  • RUSSELL 2000

    2,234.41
    +45.99 (+2.10%)
     

  • 10-Yr Bond

    4.0730
    -0.0230 (-0.56%)
     

  • NASDAQ

    18,342.94
    +60.89 (+0.33%)
     

  • VOLATILITY

    20.46
    -0.47 (-2.25%)
     

  • FTSE

    8,253.65
    +15.92 (+0.19%)
     

  • NIKKEI 225

    39,605.80
    +224.91 (+0.57%)
     

  • CAD/EUR

    0.6642
    -0.0011 (-0.17%)
     

Gritstone bio to Participate in Upcoming Investor Conferences

Gritstone bio
·1 min read
Gritstone bio
Gritstone bio

EMERYVILLE, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that management will be participating in the following investor conferences:

Goldman Sachs 44th Annual Healthcare Conference (Fireside Chat)
Fireside Chat Date and Time: Monday, June 12 at 4:00pm PT
Speaker: Andrew Allen, M.D., Ph.D., Co-founder, President and Chief Executive Officer
Location: Dana Point, CA
Webcast: https://cc.webcasts.com/gold006/061223a_js/?entity=46_YF42184

SVB Securities Therapeutics Forum (1x1s)
Conference Dates: July 11-12, 2023
Location: New York, NY

The live webcast will also be available via https://ir.gritstonebio.com/investors/events. An archived replay will be accessible for 30 days following the event.

About Gritstone bio
Gritstone is working to create the world’s most potent vaccines. We leverage our innovative vectors and payloads to train multiple arms of the immune system to attack critical disease targets and have programs in viral diseases and solid tumors. Independently and with our partners, we are advancing a portfolio of product candidates with the aim of improving patient outcomes and eliminating disease. www.gritstonebio.com

Gritstone Contacts
Investors:
George E. MacDougall
Director, Investor Relations & Corporate Communications
Gritstone bio, Inc.
ir@gritstone.com

Media:
Dan Budwick
1AB
(973) 271-6085
dan@1abmedia.com